整理 | GLP1减重宝典内容团队 7月1日，专注于肥胖、糖尿病及罕见病口服疗法的临床阶段生物制药公司 Syntis Bio 宣布，已成功完成3300万美元A轮超额认购融资。本轮融 资由 Cerberus Ventures 领投，Mansueto Investments、Woori Venture Partners 和 Apollo Labs 等新投资方加入，早期支持者 BOLD Capital Partners、W.R. Berkley Corporation、Safar Partners、Portal Innovations、Colorcon Ventures 及 Cerity Partners Ventures 也继续加码投资。 创始人之一Professor Robert S. Langer 是美国麻省理工学院（MIT）David H. Koch 生物工程研究所的联合创始人兼资深教授。他是世界顶尖 的生物医学工程学者之一，以在药物递送系统和组织工程领域的开创性工作闻名。Langer 教授拥有超过1,400项已授权或申请中的专利，其技 术已促成40多家生物科技公司的发展，是现代生物医药产业最具影响力的科学 ...

Core Viewpoint - Obesity is recognized as one of the most severe global public health crises of the 21st century, with the World Health Organization reporting that the number of overweight individuals has nearly tripled in the past fifty years, and this trend continues to rise [3][4] Group 1: Traditional Views and New Insights - The traditional view of obesity as a simple energy imbalance (overconsumption vs. insufficient expenditure) has dominated obesity prevention strategies for decades [3] - Recent research by Professor Barbara E. Corkey reveals that the causes of obesity are more complex, involving food additives and environmental endocrine disruptors that may alter metabolic regulation mechanisms [3][4] Group 2: Metabolic Disruptors - The concept of "obesogens," or obesity-inducing substances, has emerged as a critical factor in understanding obesity, as these chemicals interfere with metabolic regulation rather than merely increasing caloric intake [6][8] - These obesogens are found in food packaging, household products, and even air pollutants, entering the body through various pathways and potentially leading to fat accumulation despite healthy eating and exercise [8][9] Group 3: Sources and Impact of Obesogens - Obesogens are present in modern agriculture (fertilizers and pesticides), food packaging (plasticizers), household items (flame retardants), and cosmetics, complicating the traditional "eat less, move more" strategy [9] - Long-term exposure to these chemicals can disrupt metabolic balance, leading to persistent fat accumulation even in individuals who maintain a healthy lifestyle [8][9] Group 4: Paradigm Shift in Obesity Research - The obesity research field is undergoing a fundamental shift, moving focus from individual behavior to the broader environmental health context, as highlighted by Corkey's obesogen theory [10] - This new paradigm emphasizes the need for a systematic research framework to identify potential obesogens, understand their molecular mechanisms, and develop exposure-blocking strategies [10][11] Group 5: Comprehensive Strategies for Obesity Prevention - A multi-faceted approach is necessary to combat the global obesity epidemic, combining personal health management with societal environmental changes [12] - The integration of micro-level behavior interventions with macro-level environmental governance is essential for creating a healthier future and reshaping societal health ecosystems [12]

Core Viewpoint - The article emphasizes the importance of weight management as a national strategy in China, particularly in the context of chronic disease prevention and control, highlighting the launch of a three-year "Weight Management Year" initiative starting in 2024 [3][9]. Group 1: National Strategy and Policy - In 2024, weight management will be elevated to a national strategic level, with a three-year initiative launched by the National Health Commission in collaboration with 16 other departments [3]. - By April 2025, the "Healthy Weight Management Action" will be officially included in the "Healthy China 2030 Action" overall plan, showcasing a comprehensive policy framework at national, provincial, and municipal levels [3][11]. Group 2: Chronic Disease Burden - Chronic diseases account for over 70% of the total disease burden in China, with abnormal weight being a significant health risk [7]. - The overweight rate among adults has reached 50.7%, with central obesity affecting over 280 million people, and the hidden obesity rate (normal BMI but high body fat) at 30% [7]. - Overweight and obesity are linked to a 40%-200% increased risk of 13 types of cancer, and the obesity rate among adolescents has increased 11 times over the past 20 years [7]. Group 3: Community and Individual Responsibility - The initiative calls for a collaborative effort among government, industry, organizations, and individuals to create a supportive environment for weight management [10]. - The government aims to curb the rising obesity rate and increase public health literacy from 18% in 2024 to 30% by 2030 [11]. Group 4: Market Opportunities - By 2025, the health weight management industry is expected to experience explosive growth, creating a new health consumption market worth over 380 billion yuan, driven by policy support, technological advancements, and consumer upgrades [12]. - Notable weight loss brands are emerging, gaining popularity among health-conscious consumers [12]. Group 5: Family and Personal Actions - Families are encouraged to adopt tools for weight management and emphasize the importance of monitoring children's health [13]. - Individuals are urged to understand the risks of overweight and obesity and to manage their weight through informed dietary, exercise, and lifestyle choices [14].

整理 | GLP1减重宝典内容团队 替尔泊肽是一种GLP-1/GIP双靶点激动剂，而司美格鲁肽则是一种GLP-1受体激动剂。虽然两者都能帮助减重，但它们的分子结构、作用机制 和临床效果各有不同。替尔泊肽通过同时激活GLP-1和GIP受体发挥作用，而司美格鲁肽主要通过激活GLP-1受体来实现减重效果。 ▍不建议同时使用 替尔泊肽和司美格鲁肽都是GLP-1受体激动剂，用于体重管理，但它们的作用机制和临床应用有所不同。根据《2024年肥胖症诊疗指南》发布 的内容，这两种药物在中国均已获批用于成年原发性肥胖症患者的减重治疗。然而，由于两者的作用机制不同，混合使用这两种药物并不推 荐，因为可能会增加不良反应的风险，并影响药物效果。 ▍结构与机制的差异 在临床实践中，医生会根据患者的具体情况以及药物的特性来选择最合适的治疗方案。通常情况下，司美格鲁肽被推荐作为基础治疗，适用于 那些饮食控制不足的肥胖人群。若司美格鲁肽效果不佳或副作用较大，替尔泊肽可作为替代选择。 然而，混合使用这两种药物可能带来不可预测的风险和副作用，因此并不推荐。患者应在医生的指导下，严格按照药物说明书及专业医师的建 议使用其中一种药物，并定期监测药物 ...

整理 | GLP1减重宝典内容团队 | 16 | CXSL2500321 | XW003注射液 | 杭州先为达生物科技股 | 本品拟用于12~17岁青 | | --- | --- | --- | --- | --- | | | | | 份有限公司 | 少年肥胖患者体重管理 | | 17 | CXSL2500320 | XW003注射液 | 杭州先为达生物科技股 | 本品拟用于12~17岁青 | | | | | 份有限公司 | 少年肥胖患者体重管理 | 近日，国家药品审评中心（CDE）官网信息显示，先为达自主研发的 XW003 注射液已获批在青少年人群中开展临床试验，适应症为 12 至 17 岁肥胖青少年的体重管理。 XW003（通用名：埃诺格鲁肽注射液，原名：伊诺格鲁肽）是一款具有全球创新性质的 GLP-1 受体激动剂，具备 cAMP 偏向性，由先为达独 立开发。与传统 GLP-1 激动剂不同，XW003 选择性激活 cAMP 信号通路，同时减少 β-arrestin 的激活，有望因此提升治疗效果并带来更多代 谢获益。 目前，XW003 已完成三项 III 期临床试验，并已就成人 2 型糖尿病的血糖控制及成人 ...

Core Viewpoint - Diabetes is manageable through monitoring key health indicators and implementing scientific interventions, which can significantly reduce the risk of complications and improve quality of life [4][21]. Group 1: Key Health Indicators - The article introduces 12 essential health indicators for diabetes management, including blood sugar, blood pressure, and blood lipids, which can be monitored at home or through regular check-ups [4][16]. - Fasting blood sugar should be maintained between 4.4-7.0 mmol/L, with levels above 7.0 mmol/L indicating a need for adjustment in nighttime glucose control strategies [5]. - Blood pressure should be strictly controlled below 130/80 mmHg, especially for those with kidney disease, while LDL-C should be below 2.6 mmol/L [6]. Group 2: Metabolic Management - Body Mass Index (BMI) should ideally be maintained between 18.5-24.0, and waist circumference should be less than 90 cm for men and 85 cm for women [7]. - Regular monitoring of urine microalbumin (less than 30 mg/24h) is crucial for early detection of kidney damage [7]. - Annual eye examinations and foot nerve assessments are essential, as these often provide early warnings of complications [7][9]. Group 3: Specific Health Monitoring - Liver function should be monitored regularly, with ALT and AST levels ideally below 40 U/L, as 70% of diabetes patients may have fatty liver [10]. - Uric acid levels should be controlled below 420 μmol/L for men and 360 μmol/L for women to prevent complications [11]. - Cardiovascular health screening is vital, as diabetes patients have a 2-4 times higher risk of coronary heart disease [12]. Group 4: Management Strategies - A scientific lifestyle management system is crucial for controlling diabetes indicators, emphasizing a diet low in glycemic index, saturated fat, and sodium, while high in dietary fiber [18]. - Exercise recommendations include daily activity for at least 30 minutes, five days a week, with heart rates maintained at a safe level [19]. - Medication should be individualized, with metformin as the first-line treatment, and regular assessments every three months to adjust treatment plans based on HbA1c results [19]. Group 5: Diagnosis Standards - Diabetes diagnosis requires strict laboratory testing standards, including fasting blood sugar levels and glucose tolerance tests [20]. - For asymptomatic individuals, a single abnormal test is insufficient for diagnosis; confirmation through repeat testing is necessary [20]. Group 6: Conclusion - Continuous monitoring and management of blood sugar and related indicators are essential to prevent complications associated with diabetes, ensuring a healthier life [21].

Core Viewpoint - The article discusses the transformation of weight management from an optional service to a necessary task for public hospitals in China, driven by government policies and the need for effective obesity treatment [5][6][7]. Group 1: Policy and Implementation - The National Health Commission, along with 16 departments, has issued a plan to encourage medical institutions to establish weight management clinics by June 2025 [5]. - Various regions are accelerating the establishment of weight management clinics, with significant numbers of hospitals already providing these services [6]. - The rapid expansion of weight management clinics has led to challenges such as inconsistent patient flow and competition among departments [6][9]. Group 2: Operational Challenges - There is a shortage of specialized weight management doctors, leading to a situation where existing doctors handle multiple responsibilities [8][10]. - The operational efficiency of weight management clinics is low, as the time required for consultations with obesity patients is significantly higher than for other conditions [12]. - The market for weight management is still in its infancy, with many patients only seeking treatment after other health issues arise [12][13]. Group 3: Financial Aspects - The profitability of weight management clinics is questionable, with many struggling to generate significant revenue due to limited patient numbers [12][14]. - Some hospitals are attempting to create independent weight management departments to enhance profitability, with varying degrees of success [14][15]. - Surgical departments tend to be more profitable in the weight management sector due to the high costs associated with surgical procedures [19][20]. Group 4: Multidisciplinary Collaboration - There is a growing recognition of the need for multidisciplinary collaboration in weight management, as no single approach can address all patient needs [27][30]. - Successful models of integrated weight management centers have emerged, where various specialties work together to provide comprehensive care [29][30]. - The establishment of centralized management systems is seen as crucial for improving efficiency and patient outcomes in weight management [27][30].

Core Viewpoint - The article discusses the successful listing of TIDE Pharmaceutical on the Hong Kong Stock Exchange, highlighting its market position and future growth plans in the peptide CRDMO sector. Group 1: Company Overview - TIDE Pharmaceutical was officially listed on June 30, with an H-share issue price of HKD 30.60, resulting in a total market capitalization of HKD 43.49 billion [2] - The company focuses on peptide CRDMO services and is the third-largest specialized service provider in this field globally [5] Group 2: Financial Performance - TIDE's revenue for 2022, 2023, and 2024 is projected to be HKD 351 million, HKD 337 million, and HKD 442 million respectively, with net profits of HKD 53.98 million, HKD 48.91 million, and HKD 59.17 million [7] - The company's overseas revenue is expected to grow from HKD 263 million in 2023 to HKD 348 million in 2024, marking a growth rate of 32.4% [7] Group 3: Market Position and Strategy - TIDE plans to use approximately HKD 429 million raised from the IPO to expand facilities in China and the U.S., enhance production capacity, and develop a sales network in Europe [5] - The company is currently collaborating with seven clients on nine GLP-1 new chemical entity projects, covering various stages from preclinical research to clinical trials [10] Group 4: Industry Context - The GLP-1 drug market shows significant potential, with major products like Novo Nordisk's "semaglutide" and Eli Lilly's "tirzepatide" generating annual sales of nearly USD 30 billion and USD 16.5 billion respectively [9] - TIDE's CDMO services generated revenue of HKD 330 million in 2024, accounting for 74.6% of total revenue, with the U.S. market contributing 55% of this revenue [8]

Core Viewpoint - The STEP 5 trial demonstrates that semaglutide 2.4 mg is effective for long-term weight management in obese adults without type 2 diabetes, showing significant and sustained weight loss over a two-year period [2][3][4]. Group 1: Trial Overview - STEP 5 is a phase 3b randomized, double-blind, placebo-controlled trial involving 304 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) [3][4]. - Participants were assigned to receive either weekly subcutaneous injections of 2.4 mg semaglutide or a placebo, alongside a low-calorie diet and increased physical activity, for 104 weeks [3][4]. - The primary endpoint was the percentage change in weight and the proportion of participants achieving a weight loss of ≥5% by week 104 [3]. Group 2: Weight Loss Results - The semaglutide group experienced a weight loss of -15.2%, compared to -2.6% in the placebo group [4]. - 77.1% of participants in the semaglutide group lost at least 5% of their body weight, while only 34.4% in the placebo group achieved this [4]. Group 3: Safety and Side Effects - Common adverse events associated with semaglutide included nausea, diarrhea, vomiting, constipation, and abdominal pain [6]. - The safety profile of semaglutide in STEP 5 was consistent with previous trials, with 5.9% of patients discontinuing treatment due to adverse events [6]. Group 4: Health Improvements - Significant improvements were observed in waist circumference (-14.4 cm in the semaglutide group vs. -5.2 cm in the placebo group) and systolic blood pressure (-5.7 mmHg vs. -1.6 mmHg) [7]. - Semaglutide also improved various metabolic health markers, including HbA1c, fasting blood glucose, and lipid profiles [7]. Group 5: STEP Trial Context - The STEP program is a comprehensive phase 3 clinical development plan for semaglutide, involving approximately 4,500 overweight or obese adults across multiple trials [8].

Core Viewpoint - The recent research from the University of California, Berkeley, challenges the traditional belief that high-calorie foods are solely responsible for obesity, suggesting that the pleasure derived from eating can play a positive role in weight management [6]. Group 1: Research Findings - The study titled "Neurohypophyseal Signal Changes Drive Hedonic Devaluation in Obesity" reveals that the enjoyment experienced during eating can help maintain energy balance, redefining the relationship between food pleasure and obesity [6]. - High-fat diets were shown to impair the brain's reward system, leading to a decreased desire for high-calorie foods, despite weight gain in subjects [8][9]. - The research identified the neuropeptide NTS as a critical factor in this process, with high-fat diets significantly reducing its expression, which normally enhances dopamine neuron activity during food enjoyment [11]. Group 2: Implications for Weight Management - Restoring NTS levels through dietary intervention or gene therapy in obese mice resulted in a normal response to food, reduced overall food intake, and significant weight loss, suggesting a shift from appetite suppression to restoring the brain's reward mechanisms [12]. - This study opens new avenues for developing personalized treatments that allow individuals to enjoy food while managing their weight, potentially addressing broader metabolic diseases like diabetes and eating disorders [12].